← Back to Clinical Trials
Recruiting NCT05135351

NCT05135351 Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05135351
Status Recruiting
Phase
Sponsor University of Nebraska
Condition Multiple Myeloma
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2022-06-07
Primary Completion 2028-07

Trial Parameters

Condition Multiple Myeloma
Sponsor University of Nebraska
Study Type INTERVENTIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 19 Years
Max Age N/A
Start Date 2022-06-07
Completion 2028-07
Interventions
Resistant StarchMaltodextrin

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma. This study hypothesises that prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity at time of stem cell engraftment. To test this, participants will either have RS or a placebo (maltodextrin) mixed into a food item of their choice for approximately 10 days prior to stem cell infusion and continue to the first day of neutrophil engraftment. The study will look at the difference in gut microbiome diversity between the RS and placebo arm collected at the engraftment timepoint, dietary evaluation to assess the impact of subject diet on microbiome response to intervention and serum sample collection to assess differences to gut permeability during transplant.

Eligibility Criteria

Inclusion Criteria: 1. Willing to provide informed consent 2. Willing to comply with all study procedures and be available for the duration of the study 3. Has pathologically confirmed multiple myeloma, Non-Hodgkin lymphoma (DLBCL, mantle cell lymphoma, follicular lymphoma, or peripheral T-cell lymphoma), or Hodgkin lymphoma as determined on medical record review per standard of care transplant procedures (no tissue required for study) 4. Meeting a standard-of-care indication for autologous stem cell transplantation for the above diseases as determined by the investigator 5. Adult Individuals (male or female) at least 19 years of age 6. Meeting indications and recommended for first autologous stem cell transplantation by investigator Exclusion Criteria: 1. History of bariatric surgery (i.e. gastric banding, sleeve gastrectomy, Roux-en-Y bypass), chronic gastrointestinal disease including chronic diarrheal illness or inflammatory bowel disease 2. Previous intolerance to fiber supplement

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology